Lynching victory.

This case report of a patient with MGMT-unmethylated IDH-wildtype glioblastoma multiforme (GBM) in the setting of Lynch syndrome (more specifically a deleterious mutation in MSH6 involved in DNA mismatch repair) details the achievement of a thus-far >2 year response to standard post-resection chemoradiation when delivered with the addition of olaparib, a PARP-inhibitor known to exploit the DNA repair deficiencies associated with Lynch syndrome. | File, JCO Precis Oncol 2020